Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Anyone asking what is BPC 157 meets the same short answer everywhere: it is a synthetic pentadecapeptide, a chain of fifteen amino acids corresponding to a partial sequence of a larger protein identified in gastric juice. The initials stand for Body Protection Compound, a name assigned by the University of Zagreb group that first characterized the fragment in the early 1990s. That answer is incomplete, because what has kept the peptide in the literature for three decades is not its size but two properties: it survives conditions that destroy most peptides, and its effects in animal models outlast the molecule itself.
This 2026 update summarizes what the peptide is, what its structure explains, which domains account for the published record, and what reviews appearing in 2025 and 2026 added, including a pharmacokinetic puzzle that remains unresolved. Everything described here reflects in vitro and animal-model work. BPC-157 is supplied for research use only, not for human consumption, and no statement below describes an outcome in people.
Molecular Identity: What BPC-157 Is Made Of
BPC-157 carries the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). Two structural features dominate its behavior. The first is a high proline content, including three consecutive prolines at positions 3 through 5, which restricts backbone rotation and gives the chain a rigid, polyproline-like conformation. The second is its charge profile: with a single lysine and two adjacent aspartates, the peptide is close to neutral, slightly positive, at physiological pH. The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Class | Synthetic pentadecapeptide |
| Sequence length | 15 amino acids |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 |
| Approximate molecular weight | About 1419.5 Da |
| Origin | Partial sequence of body protection compound found in gastric juice |
| Notable structural feature | Three consecutive prolines at positions 3 to 5 |
| Physical form | Lyophilized white powder, water soluble |
| Research classification | Regenerative and cytoprotective research peptide |
The polyproline segment is the likely explanation for the property most often cited about this compound: it remains intact after exposure to gastric juice at pH 1 to 2 with pepsin, conditions under which most peptides are rapidly cleaved. A 2026 review in Pharmaceutics by Mateescu and colleagues attributed that resistance to the conformational rigidity the proline run imposes, and identified the peptide’s principal chemical liability for laboratory work: hydrolysis of the aspartyl bond at the Asp10-Asp11 junction under acidic and neutral conditions, a reason reconstituted material is kept cold and handled with attention to solution pH.
What Is BPC 157 Studied For? The Four Research Domains
Gastrointestinal Models
The oldest branch of the literature concerns the digestive tract. Sikiric, Seiwerth, Grabarevic and colleagues reported in Life Sciences (1994) that the peptide attenuated gastric and duodenal lesions in rats challenged with restraint stress, cysteamine, and ethanol. Later work extended the models to intestinal anastomosis healing, and the Zagreb group came to call the pattern organoprotection: a protective response seen across organ systems rather than confined to the mucosa.
Musculoskeletal Models
Tendon, ligament, muscle, and bone models form the largest body of work. Staresinic and colleagues reported accelerated healing of transected rat Achilles tendon in the Journal of Orthopaedic Research (2003), with in vitro evidence of tendocyte outgrowth. Krivic and colleagues examined tendon-to-bone healing (2006), and Cerovecki and colleagues extended the work to medial collateral ligament models (2010). A systematic review by Vasireddi and colleagues in the HSS Journal (2025) screened 544 articles and included 36, of which 35 were preclinical; those studies used rat models almost exclusively, with one rabbit bone-defect study, and reported effects on tendon outgrowth, cell survival, and cell migration, on ligament and muscle injury models, and an osteogenic response in bone defects. The authors linked those observations to increased growth hormone receptor expression, angiogenic pathway activity, and reduced inflammatory cytokines in the tissues examined.
Neural Models
Sikiric and colleagues reviewed brain-gut axis work in Current Neuropharmacology (2016), describing modulation of serotonergic and dopaminergic signaling in rodents. Later reviews collected rat experiments on peripheral nerve regeneration after transection and on cerebral ischemia and reperfusion models produced by bilateral carotid clamping.
Vascular Models
Vascular biology has produced the most mechanistically detailed findings. Brcic and colleagues described modulation of angiogenesis during muscle and tendon healing in rats (2009), and a 2017 report in the Journal of Molecular Medicine connected pro-angiogenic activity to VEGFR2 expression using chorioallantoic membrane and tube-formation assays plus a rat hindlimb ischemia model.
What the 2025 and 2026 Reviews Added
A Pharmacokinetic Puzzle
The most consequential recent addition is a disconnect between exposure and effect. The 2026 Pharmaceutics review reported a plasma half-life under 30 minutes in preclinical characterization, rapid proteolytic hydrolysis into a small set of identified fragments, elimination by urinary and biliary routes, and bioavailability that differed substantially between rodent and canine models. Set against responses lasting hours to days in animal studies, that short residence time implies the peptide acts as a trigger for downstream repair cascades rather than through sustained target occupancy.
An Unidentified Molecular Target
The same review made a point easy to miss in summaries of this compound: no high-affinity binding site has been identified, and the molecular target remains formally unknown. What the literature describes instead is a set of pathways in which activity is reproducibly observed: the VEGFR2 axis with FAK-paxillin adhesion signaling, the transcription factor Egr-1 with its downstream growth factors, the nitric oxide system with heme oxygenase-1, and growth hormone receptor expression. A compound defined by pathway associations rather than by a receptor is unusual, which is why mechanistic papers keep accumulating without converging on a single answer.
The Shape of the Evidence Base
Both recent reviews agree on the composition of the record. The published work is overwhelmingly preclinical and conducted in rodent models, and a large share originates from or connects to the original Zagreb group, with independent replication still limited. Characterization gaps remain, including the peptide’s three-dimensional solution structure. These are not footnotes; they define how far any preclinical observation can be extended.
Laboratory Handling and Verification
BPC-157 is supplied as a lyophilized powder and is water soluble, so it does not require a carrier solvent such as DMSO for aqueous preparation. Sealed vials are kept frozen, commonly at -20 C or below; reconstituted solutions are held at 2 to 8 C and aliquoted into single-use volumes to avoid repeated freeze-thaw cycles. Given the Asp10-Asp11 hydrolysis liability, prolonged storage in solution is avoided regardless of temperature. Diluent choice and concentration math are covered in the bacteriostatic water guide, the underlying chemistry in the reconstitution chemistry guide, and temperatures in the storage and handling guide.
Verification matters more here than for most compounds, because the entire literature rests on a single 15-residue sequence. Research-grade material is characterized by HPLC for purity and by mass spectrometry against the expected mass near 1419.5 Da, and a lot-specific certificate of analysis should document both for the lot in hand; the COA reading guide explains how to interpret those values.
Three decades after the first reports, the answer to what is BPC 157 remains a fifteen-amino-acid research peptide with a broad preclinical footprint, a documented resistance to gastric conditions, and an unresolved mechanism. Laboratories sourcing BPC-157, the combined BPC-157 and TB-500 preparation, or other compounds from the research peptide catalog handle it strictly as a laboratory material, for research use only, not for human consumption.
Frequently Asked Questions
What is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide of fifteen amino acids corresponding to a partial sequence of a protein found in gastric juice. It was first characterized at the University of Zagreb in the early 1990s and has since been studied in gastrointestinal, musculoskeletal, neural, and vascular animal models. It is a research compound, not a medicine.
What is the BPC-157 peptide sequence and molecular weight?
The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), the molecular formula is C62H98N16O22, and the molecular weight is approximately 1419.5 Da. Mass spectrometry against that value is a standard identity check for research-grade material.
Why is BPC-157 described as stable in gastric juice?
Reports describe the peptide remaining intact after exposure to gastric juice at pH 1 to 2 with pepsin, conditions that cleave most peptides quickly. A 2026 review attributed this to the rigid conformation imposed by three consecutive prolines near the N-terminus.
What is BPC-157 studied for?
In preclinical research it is studied for cytoprotection and organoprotection in gastrointestinal injury models, for tendon, ligament, muscle, and bone healing in rodent models, for nerve injury and ischemia models, and for angiogenesis in endothelial assays. All of this work is in vitro or in laboratory animals.
Does BPC-157 have a known receptor?
No high-affinity binding site has been identified, and a 2026 review states that the molecular target remains formally unknown. The literature instead describes consistent activity across several pathways, including VEGFR2 with FAK-paxillin signaling, the Egr-1 transcription factor and its growth factors, and the nitric oxide system.
Is BPC-157 intended for human use?
No. BPC-157 is offered strictly as a laboratory research material, for research use only, not for human consumption. The published record consists of in vitro and animal-model studies.
References and Further Reading
- Sikiric P, Seiwerth S, Grabarevic Z and colleagues on the BPC fragment and gastric and duodenal lesions in rats, Life Sciences (1994). PubMed: BPC 157 gastric duodenal lesions rats Sikiric
- Staresinic M and colleagues on transected rat Achilles tendon healing and tendocyte outgrowth, Journal of Orthopaedic Research (2003). PubMed: BPC 157 Achilles tendon rat tendocyte
- Krivic A and colleagues on tendon-to-bone healing in rats (2006) and Cerovecki T and colleagues on medial collateral ligament models (2010). PubMed: BPC 157 tendon to bone ligament rat
- Brcic L and colleagues on angiogenesis in muscle and tendon healing, Journal of Physiology and Pharmacology (2009). PubMed: BPC 157 angiogenesis muscle tendon healing
- Sikiric P and colleagues on brain-gut axis findings, Current Neuropharmacology (2016), plus later central nervous system reviews. PubMed: BPC 157 brain gut axis central nervous system
- Vasireddi N, Hahamyan H, Salata MJ and colleagues, systematic review of the preclinical musculoskeletal literature, HSS Journal (2025). PubMed: BPC-157 orthopaedic sports medicine systematic review
- Mateescu and colleagues on physicochemical properties, formulation challenges, and proposed mechanisms, Pharmaceutics (2026). PubMed: BPC-157 biopharmaceutical formulation review
